Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme.
- 2 May 1987
- Vol. 294 (6580) , 1119-1120
- https://doi.org/10.1136/bmj.294.6580.1119
Abstract
Inhibitors of angiotensin converting enzyme may cause angio-oedema. To see if this might be due to potentiation of the tissue effects of bradykinin the thickness of weals raised by intradermal injection of saline or 1, 3, or 10 micrograms bradykinin was measured before and three times after single doses of captopril, enalapril, or placebo. The mean thickness increased with increasing doses of bradykinin. It did not change with time after the administration of placebo or captopril but increased from 0.61 mm before enalapril to 1.12 mm two and a half hours and 1.06 mm five hours after enalapril was given. Five subjects flushed when given bradykinin after captopril and four after enalapril, but none flushed when given bradykinin after placebo. It is concluded that angiotensin converting enzyme inhibitors potentiate the effects of intradermal bradykinin in vivo and that this may partially explain why they cause angio-oedema in susceptible patients.This publication has 7 references indexed in Scilit:
- Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.BMJ, 1987
- Cough and Wheeze Caused by Inhibitors of Angiotensin-Converting EnzymeNew England Journal of Medicine, 1986
- Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors A ReviewClinical Pharmacokinetics, 1985
- Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilationClinical Pharmacology & Therapeutics, 1982
- HISTAMINE WEAL FORMATION AND ABSORPTION IN MANBritish Journal of Pharmacology, 1980
- Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme).1971
- Immunochemistry of Bradykinin and Immunologic Activation of the Kinin SystemPublished by Springer Nature ,1970